GTCB (from SI): >> From: DewDiligence_on_SI 6/2/2006 2:30:43 PM To: Sam Citron who wrote (2517) of 2518 > How do you see this news impacting chance for US approval?< The U.S. ATryn program figures to be an easier sell to the regulators for two reasons: 1. The U.S. phase-3 trial is larger and contains a control arm. 2. The unmet medical need in the U.S. is greater because (unlike Europe) plasma-derived antithrombin is rarely available in the U.S. I think the probability of FDA approval for ATryn in 2008 is about 85%. Regards, Dew <<